In this insightful discussion, Carol Houts, Chief Strategy Officer for Germfree, draws from over 30 years of experience in the pharmaceutical industry to address the critical barriers to patient access in the cell and gene therapy space. Specifically, Carol discusses Germfree’s innovative work in decentralized manufacturing. She highlights the urgent need for accessible clinical sites, significant cost reductions, and streamlined regulatory frameworks that can make advanced therapies more available to patients.

As Carol explains, one of the main challenges in the cell and gene therapy landscape is ensuring therapies can reach patients regardless of geographical limitations. Traditional, centralized manufacturing models often restrict access, particularly for patients in remote or underserved areas. However, Germfree’s decentralized manufacturing approach allows for far greater flexibility, as it brings production closer to clinical sites. This shift enables faster and more widespread patient access. Furthermore, this model not only reduces logistical constraints but also helps minimize the high costs often associated with transporting fragile, patient-specific therapies over long distances.

Watch the full video below to learn how Germfree is helping bridge the gaps in cell and gene therapy access through flexible manufacturing models, innovative partnerships, and advanced technology systems.